| 1 | Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial | 21.6 | 5 | Citations (PDF) |
| 2 | Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study | 21.6 | 19 | Citations (PDF) |
| 3 | Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids | 3.3 | 20 | Citations (PDF) |
| 4 | Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateBlood, 2024, 143, 1713-1725 | 4.2 | 83 | Citations (PDF) |
| 5 | Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial | 21.6 | 0 | Citations (PDF) |
| 6 | Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial | 21.6 | 31 | Citations (PDF) |
| 7 | Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years | 7.9 | 19 | Citations (PDF) |
| 8 | Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial | 10.4 | 87 | Citations (PDF) |
| 9 | High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network | 21.6 | 41 | Citations (PDF) |
| 10 | Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity | 22.8 | 103 | Citations (PDF) |
| 11 | Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial | 39.5 | 76 | Citations (PDF) |
| 12 | Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes | 1.0 | 8 | Citations (PDF) |
| 13 | Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study | 4.1 | 3 | Citations (PDF) |
| 14 | Genetic and phenotypic attributes of splenic marginal zone lymphomaBlood, 2022, 139, 732-747 | 4.2 | 87 | Citations (PDF) |
| 15 | A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia | 1.5 | 5 | Citations (PDF) |
| 16 | Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma | 3.3 | 54 | Citations (PDF) |
| 17 | The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells | 3.5 | 15 | Citations (PDF) |
| 18 | Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas | 3.0 | 18 | Citations (PDF) |
| 19 | Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study | 3.3 | 4 | Citations (PDF) |
| 20 | The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study | 4.0 | 4 | Citations (PDF) |
| 21 | Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma | 43.7 | 469 | Citations (PDF) |
| 22 | Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma | 4.1 | 2 | Citations (PDF) |
| 23 | Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials | 1.5 | 5 | Citations (PDF) |
| 24 | Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group | 4.0 | 1 | Citations (PDF) |
| 25 | Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | 39.5 | 241 | Citations (PDF) |
| 26 | Finding a consensus on time‐to‐event endpoints definitions in marginal zone lymphoma: A Delphi method | 2.2 | 1 | Citations (PDF) |
| 27 | Comparing apples and oranges: The ZUMA‐7, TRANSFORM and BELINDA trials | 2.2 | 13 | Citations (PDF) |
| 28 | Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network | 3.3 | 24 | Citations (PDF) |
| 29 | Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL | 1.5 | 19 | Citations (PDF) |
| 30 | Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study | 2.6 | 11 | Citations (PDF) |
| 31 | A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma | 5.1 | 31 | Citations (PDF) |
| 32 | A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma | 39.5 | 311 | Citations (PDF) |
| 33 | Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study | 4.1 | 20 | Citations (PDF) |
| 34 | Deep-Learning <sup>18</sup>F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma | 5.6 | 120 | Citations (PDF) |
| 35 | Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSABlood, 2021, 137, 2307-2320 | 4.2 | 68 | Citations (PDF) |
| 36 | Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review | 1.3 | 24 | Citations (PDF) |
| 37 | Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma | 1.5 | 16 | Citations (PDF) |
| 38 | Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21) | 1.5 | 2 | Citations (PDF) |
| 39 | Real‐life targeted next‐generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network | 2.4 | 13 | Citations (PDF) |
| 40 | Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial | 3.3 | 15 | Citations (PDF) |
| 41 | Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma | 2.4 | 9 | Citations (PDF) |
| 42 | Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/<scp>T‐Cell</scp> lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (<scp>SFGM‐TC</scp>) | 6.1 | 15 | Citations (PDF) |
| 43 | Aspects biologiques et thérapeutiques des lymphomes de la zone marginale | 0.1 | 0 | Citations (PDF) |
| 44 | Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study | 30.9 | 15 | Citations (PDF) |
| 45 | Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma | 2.4 | 178 | Citations (PDF) |
| 46 | New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT | 4.0 | 28 | Citations (PDF) |
| 47 | Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP | 5.1 | 8 | Citations (PDF) |
| 48 | The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma | 6.9 | 66 | Citations (PDF) |
| 49 | Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas | 0.6 | 26 | Citations (PDF) |
| 50 | Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma | 2.4 | 103 | Citations (PDF) |
| 51 | Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years | 4.0 | 8 | Citations (PDF) |
| 52 | Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial | 9.2 | 46 | Citations (PDF) |
| 53 | Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma | 2.2 | 10 | Citations (PDF) |
| 54 | Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial | 39.5 | 454 | Citations (PDF) |
| 55 | Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study | 1.0 | 2 | Citations (PDF) |
| 56 | Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study | 2.4 | 17 | Citations (PDF) |
| 57 | Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project | 4.1 | 36 | Citations (PDF) |
| 58 | Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | 10.2 | 301 | Citations (PDF) |
| 59 | Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis | 2.9 | 13 | Citations (PDF) |
| 60 | Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group | 9.2 | 19 | Citations (PDF) |
| 61 | Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma | 5.1 | 347 | Citations (PDF) |
| 62 | NF-κB in the New Era of Cancer Therapy | 10.6 | 70 | Citations (PDF) |
| 63 | Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction | 1.8 | 6 | Citations (PDF) |
| 64 | CD19-directed CAR T-cell therapy in B-cell NHL | 2.2 | 32 | Citations (PDF) |
| 65 | Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis | 5.1 | 90 | Citations (PDF) |
| 66 | Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <scp>LYSA</scp> group | 2.2 | 11 | Citations (PDF) |
| 67 | Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study | 1.5 | 17 | Citations (PDF) |
| 68 | Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up | 7.9 | 46 | Citations (PDF) |
| 69 | Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial | 9.2 | 285 | Citations (PDF) |
| 70 | Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) | 1.6 | 14 | Citations (PDF) |
| 71 | Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews | 1.7 | 7 | Citations (PDF) |
| 72 | Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA | 1.5 | 10 | Citations (PDF) |
| 73 | Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment | 4.1 | 39 | Citations (PDF) |
| 74 | Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma | 6.7 | 20 | Citations (PDF) |
| 75 | Lymphomas with kidney involvement: the French multicenter retrospective LyKID study | 1.5 | 9 | Citations (PDF) |
| 76 | High total metabolic tumor volume at baseline predicts survival independent of response to therapyBlood, 2020, 135, 1396-1405 | 4.2 | 162 | Citations (PDF) |
| 77 | Impact of the COVID-19 Outbreak on the Management of Patients with Cancer | 3.3 | 117 | Citations (PDF) |
| 78 | Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study | 9.2 | 86 | Citations (PDF) |
| 79 | Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study | 3.0 | 14 | Citations (PDF) |
| 80 | Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients | 4.7 | 6 | Citations (PDF) |
| 81 | Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study | 4.1 | 22 | Citations (PDF) |
| 82 | GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors | 26.2 | 68 | Citations (PDF) |
| 83 | Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor | 3.3 | 16 | Citations (PDF) |
| 84 | Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two <scp>LYSA</scp> studies | 2.7 | 13 | Citations (PDF) |
| 85 | Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study | 10.4 | 85 | Citations (PDF) |
| 86 | Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH) | 2.4 | 31 | Citations (PDF) |
| 87 | Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode | 1.8 | 10 | Citations (PDF) |
| 88 | Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination | 3.2 | 7 | Citations (PDF) |
| 89 | Definition of a minimal genes set for mature lymphoid blood diseases | 0.0 | 4 | Citations (PDF) |
| 90 | Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study | 2.4 | 51 | Citations (PDF) |
| 91 | Curing diffuse large B-cell lymphomas in elderly patients | 2.9 | 13 | Citations (PDF) |
| 92 | An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphomaBlood, 2018, 132, 1486-1494 | 4.2 | 31 | Citations (PDF) |
| 93 | Optimizing initial therapy in DLBCL | 1.8 | 17 | Citations (PDF) |
| 94 | High‐dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the<scp>EBMT</scp>Lymphoma Working Party and<scp>FIL</scp>‐<scp>GITMO</scp> | 2.4 | 24 | Citations (PDF) |
| 95 | Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome | 1.5 | 8 | Citations (PDF) |
| 96 | Burden of illness of follicular lymphoma and marginal zone lymphoma | 1.5 | 23 | Citations (PDF) |
| 97 | Clinical aspects and therapy of gastrointestinal MALT lymphoma | 1.8 | 53 | Citations (PDF) |
| 98 | Conduire des études épidémiologiques après cancer en France : modalités, difficultés et propositions de solutions. Les enseignements de l’étude SIMONAL sur les toxicités tardives des traitements du lymphome non Hodgkinien | 0.6 | 3 | Citations (PDF) |
| 99 | Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaBlood, 2017, 129, 2224-2232 | 4.2 | 274 | Citations (PDF) |
| 100 | Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS | 1.8 | 73 | Citations (PDF) |
| 101 | Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma | 10.2 | 243 | Citations (PDF) |
| 102 | Management of aggressive lymphoma in very elderly patients | 2.2 | 10 | Citations (PDF) |
| 103 | BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial | 10.2 | 26 | Citations (PDF) |
| 104 | International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) | 10.2 | 322 | Citations (PDF) |
| 105 | Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma | 43.7 | 380 | Citations (PDF) |
| 106 | A MALT lymphoma prognostic indexBlood, 2017, 130, 1409-1417 | 4.2 | 174 | Citations (PDF) |
| 107 | Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial | 23.6 | 86 | Citations (PDF) |
| 108 | Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients | 1.7 | 14 | Citations (PDF) |
| 109 | Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma | 2.9 | 25 | Citations (PDF) |
| 110 | HHV-6 reactivation as a cause of fever in autologous hematopoietic stem cell transplant recipients | 2.9 | 17 | Citations (PDF) |
| 111 | Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting | 1.7 | 8 | Citations (PDF) |
| 112 | VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers | 1.7 | 4 | Citations (PDF) |
| 113 | Tailoring treatment for MALT lymphoma patients: where do we stand now? | 1.7 | 1 | Citations (PDF) |
| 114 | Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses | 1.7 | 21 | Citations (PDF) |
| 115 | A phase <scp>II</scp>, single‐arm, multicentre study of coltuximab ravtansine (<scp>SAR</scp>3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma | 2.4 | 51 | Citations (PDF) |
| 116 | Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma | 6.1 | 47 | Citations (PDF) |
| 117 | Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study | 4.1 | 59 | Citations (PDF) |
| 118 | Optimizing therapy for nodal marginal zone lymphomaBlood, 2016, 127, 2064-2071 | 4.2 | 64 | Citations (PDF) |
| 119 | Radiothérapie des lymphomes malins non hodgkiniens localisés de type MALT (gastriques et de la région orbitaire) | 1.3 | 3 | Citations (PDF) |
| 120 | European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma | 4.1 | 46 | Citations (PDF) |
| 121 | Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network | 52.8 | 373 | Citations (PDF) |
| 122 | Pulmonary mucosa-associated lymphoid tissue lymphoma revisited | 12.1 | 88 | Citations (PDF) |
| 123 | Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment | 1.5 | 0 | Citations (PDF) |
| 124 | Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study | 9.2 | 400 | Citations (PDF) |
| 125 | Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis | 10.2 | 68 | Citations (PDF) |
| 126 | Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA | 10.2 | 13 | Citations (PDF) |
| 127 | Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone | 1.5 | 25 | Citations (PDF) |
| 128 | Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 StudyBlood, 2016, 128, 1213-1213 | 4.2 | 9 | Citations (PDF) |
| 129 | Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams GroupBlood, 2016, 128, 145-145 | 4.2 | 38 | Citations (PDF) |
| 130 | Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the Lysa GroupBlood, 2016, 128, 2987-2987 | 4.2 | 1 | Citations (PDF) |
| 131 | First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from LysaBlood, 2016, 128, 471-471 | 4.2 | 13 | Citations (PDF) |
| 132 | In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas | 2.4 | 20 | Citations (PDF) |
| 133 | Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa StudiesBlood, 2016, 128, 927-927 | 4.2 | 0 | Citations (PDF) |
| 134 | Tolerance and Efficacy of L-Asparaginase during Induction of Extra-Nodal Natural Killer (NK/T) Lymphoma, Nasal Type, in Real-Life ExperienceBlood, 2016, 128, 5351-5351 | 4.2 | 0 | Citations (PDF) |
| 135 | DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic featuresBlood, 2015, 125, 1922-1931 | 4.2 | 63 | Citations (PDF) |
| 136 | High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaBlood, 2015, 126, 604-611 | 4.2 | 151 | Citations (PDF) |
| 137 | Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease | 17.1 | 161 | Citations (PDF) |
| 138 | Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study | 6.1 | 87 | Citations (PDF) |
| 139 | Ibrutinib : applications cliniques et perspectives de développement dans les hémopathies malignes B | 0.6 | 2 | Citations (PDF) |
| 140 | Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study | 9.2 | 100 | Citations (PDF) |
| 141 | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) | 3.5 | 60 | Citations (PDF) |
| 142 | Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma | 1.5 | 24 | Citations (PDF) |
| 143 | Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma | 1.5 | 4 | Citations (PDF) |
| 144 | Inhibitors of <scp>BCR</scp> signalling interrupt the survival signal mediated by the micro‐environment in mantle cell lymphoma | 4.5 | 52 | Citations (PDF) |
| 145 | Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study | 1.5 | 7 | Citations (PDF) |
| 146 | Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party | 3.3 | 51 | Citations (PDF) |
| 147 | Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies | 3.6 | 83 | Citations (PDF) |
| 148 | Analytical Performance of Nanostring's Companion Diagnostic (CDx) Lymphoma Subtyping Test (LST) with Diffuse Large B-Cell Lymphoma Core Needle Biopsy SamplesBlood, 2015, 126, 1481-1481 | 4.2 | 1 | Citations (PDF) |
| 149 | Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin LymphomaBlood, 2015, 126, 1532-1532 | 4.2 | 5 | Citations (PDF) |
| 150 | Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa GroupBlood, 2015, 126, 338-338 | 4.2 | 20 | Citations (PDF) |
| 151 | Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral StudyBlood, 2015, 126, 517-517 | 4.2 | 2 | Citations (PDF) |
| 152 | Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?Blood, 2015, 126, 2886-2886 | 4.2 | 1 | Citations (PDF) |
| 153 | Metabolic Tumor Volume Influences Response to Brentuximab-Vedotin in Relapsed Refractory Hodgkin LymphomaBlood, 2015, 126, 588-588 | 4.2 | 0 | Citations (PDF) |
| 154 | Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment | 1.5 | 87 | Citations (PDF) |
| 155 | Long‐term follow‐up and second malignancies in 487 patients with hairy cell leukaemia | 2.4 | 58 | Citations (PDF) |
| 156 | Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome? | 1.5 | 15 | Citations (PDF) |
| 157 | Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type | 14.1 | 89 | Citations (PDF) |
| 158 | Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma | 5.6 | 10 | Citations (PDF) |
| 159 | Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study | 26.0 | 250 | Citations (PDF) |
| 160 | Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases | 1.5 | 21 | Citations (PDF) |
| 161 | GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-κB-dependent induction of HIF-1α | 10.4 | 60 | Citations (PDF) |
| 162 | Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa StudyBlood, 2014, 124, 146-146 | 4.2 | 19 | Citations (PDF) |
| 163 | Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network StudyBlood, 2014, 124, 1625-1625 | 4.2 | 1 | Citations (PDF) |
| 164 | Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell LymphomaBlood, 2014, 124, 3067-3067 | 4.2 | 15 | Citations (PDF) |
| 165 | Promising Results of Ibrutinib in Three Patients with Secondary Central Nervous System Mantle Cell LymphomaBlood, 2014, 124, 3105-3105 | 4.2 | 2 | Citations (PDF) |
| 166 | A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic MalignanciesBlood, 2014, 124, 4417-4417 | 4.2 | 8 | Citations (PDF) |
| 167 | A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell LymphomaBlood, 2014, 124, 4458-4458 | 4.2 | 8 | Citations (PDF) |
| 168 | Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working PartyBlood, 2014, 124, 678-678 | 4.2 | 6 | Citations (PDF) |
| 169 | First Lymphoma Study Association workshops Deauville (France), 10th-12th October 2013 – part 2 | 0.0 | 0 | Citations (PDF) |
| 170 | Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa StudyBlood, 2014, 124, 1657-1657 | 4.2 | 0 | Citations (PDF) |
| 171 | High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective StudyBlood, 2014, 124, 2526-2526 | 4.2 | 2 | Citations (PDF) |
| 172 | Tumour lysis syndrome and acute kidney injury in high‐risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en <scp>R</scp>éanimation Respiratoire et <scp>O</scp>nco‐<scp>H</scp>ématologique | 2.4 | 104 | Citations (PDF) |
| 173 | A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial | 5.1 | 132 | Citations (PDF) |
| 174 | Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial | 26.0 | 286 | Citations (PDF) |
| 175 | Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) | 10.2 | 32 | Citations (PDF) |
| 176 | ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma | 10.2 | 279 | Citations (PDF) |
| 177 | ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) | 10.2 | 203 | Citations (PDF) |
| 178 | At diagnosis, diffuse large <scp>B</scp>‐cell lymphoma patients show impaired rituximab‐mediated <scp>NK</scp>‐cell cytotoxicity | 3.2 | 22 | Citations (PDF) |
| 179 | Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study | 10.2 | 87 | Citations (PDF) |
| 180 | Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA | 10.2 | 32 | Citations (PDF) |
| 181 | MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?Blood, 2013, 121, 2165-2166 | 4.2 | 26 | Citations (PDF) |
| 182 | Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival | 2.4 | 127 | Citations (PDF) |
| 183 | Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC | 1.5 | 18 | Citations (PDF) |
| 184 | Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral StudyBlood, 2013, 122, 764-764 | 4.2 | 8 | Citations (PDF) |
| 185 | Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 PatientsBlood, 2013, 122, 3005-3005 | 4.2 | 0 | Citations (PDF) |
| 186 | Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes | 4.2 | 0 | Citations (PDF) |
| 187 | Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B StudyBlood, 2013, 122, 3663-3663 | 4.2 | 0 | Citations (PDF) |
| 188 | Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 CasesBlood, 2013, 122, 5308-5308 | 4.2 | 0 | Citations (PDF) |
| 189 | BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma | 4.9 | 5 | Citations (PDF) |
| 190 | Lenalidomide in Diffuse Large B-Cell Lymphoma | 1.5 | 18 | Citations (PDF) |
| 191 | Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patientsBlood, 2012, 119, 5126-5132 | 4.2 | 180 | Citations (PDF) |
| 192 | Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up | 10.2 | 52 | Citations (PDF) |
| 193 | MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantationBlood, 2012, 119, 4619-4624 | 4.2 | 153 | Citations (PDF) |
| 194 | Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial | 1.0 | 18 | Citations (PDF) |
| 195 | Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)Blood, 2012, 120, 151-151 | 4.2 | 53 | Citations (PDF) |
| 196 | Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa StudyBlood, 2012, 120, 152-152 | 4.2 | 13 | Citations (PDF) |
| 197 | A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP StudyBlood, 2012, 120, 1617-1617 | 4.2 | 2 | Citations (PDF) |
| 198 | Lymphoma Occurring Over the Age of 90: Clinical Presentation and OutcomeBlood, 2012, 120, 1582-1582 | 4.2 | 0 | Citations (PDF) |
| 199 | Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03–6B GELA Study.Blood, 2012, 120, 2723-2723 | 4.2 | 1 | Citations (PDF) |
| 200 | Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 PatientsBlood, 2012, 120, 3921-3921 | 4.2 | 0 | Citations (PDF) |
| 201 | Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial | 26.0 | 504 | Citations (PDF) |
| 202 | Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial | 52.8 | 336 | Citations (PDF) |
| 203 | Non-MALT marginal zone lymphoma | 2.8 | 25 | Citations (PDF) |
| 204 | Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcomeBlood, 2011, 117, 1595-1604 | 4.2 | 185 | Citations (PDF) |
| 205 | Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma | 2.2 | 6 | Citations (PDF) |
| 206 | SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma | 4.2 | 296 | Citations (PDF) |
| 207 | R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2BBlood, 2011, 118, 2632-2632 | 4.2 | 5 | Citations (PDF) |
| 208 | Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)Blood, 2011, 118, 268-268 | 4.2 | 3 | Citations (PDF) |
| 209 | Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and EfficacyBlood, 2011, 118, 2718-2718 | 4.2 | 2 | Citations (PDF) |
| 210 | An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,Blood, 2011, 118, 3715-3715 | 4.2 | 6 | Citations (PDF) |
| 211 | Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL)Blood, 2011, 118, 2673-2673 | 4.2 | 0 | Citations (PDF) |
| 212 | The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working PartyBlood, 2011, 118, 502-502 | 4.2 | 1 | Citations (PDF) |
| 213 | Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA studyBlood, 2010, 116, 1092-1104 | 4.2 | 132 | Citations (PDF) |
| 214 | Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma GroupBlood, 2010, 116, 1479-1488 | 4.2 | 186 | Citations (PDF) |
| 215 | Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010, 116, 2040-2045 | 4.2 | 1,362 | Citations (PDF) |
| 216 | Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | 1.0 | 56 | Citations (PDF) |
| 217 | Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)Blood, 2010, 116, 110-110 | 4.2 | 28 | Citations (PDF) |
| 218 | Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL)Blood, 2010, 116, 2860-2860 | 4.2 | 3 | Citations (PDF) |
| 219 | Second-line treatment paradigms for diffuse large B-cell lymphomas | 4.4 | 27 | Citations (PDF) |
| 220 | Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.Blood, 2009, 114, 1649-1649 | 4.2 | 6 | Citations (PDF) |
| 221 | Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.Blood, 2009, 114, 884-884 | 4.2 | 41 | Citations (PDF) |
| 222 | Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis.Blood, 2008, 112, 1780-1780 | 4.2 | 3 | Citations (PDF) |
| 223 | CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d’Etude des Lymphomes de l’Adulte | 21.6 | 247 | Citations (PDF) |
| 224 | Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma | 4.1 | 35 | Citations (PDF) |
| 225 | Clinical Presentation and Management of Marginal Zone Lymphomas | 2.9 | 105 | Citations (PDF) |
| 226 | Clinicopathologic Features of Waldenström's Macroglobulinemia and Marginal Zone Lymphoma: Are They Distinct or the Same Entity? | 1.9 | 50 | Citations (PDF) |
| 227 | Splenic marginal-zone lymphoma: a distinct clinical and pathological entity | 26.0 | 171 | Citations (PDF) |
| 228 | Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001 | 1.5 | 29 | Citations (PDF) |
| 229 | Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeBlood, 2003, 102, 2741-2745 | 4.2 | 410 | Citations (PDF) |
| 230 | Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients | 1.9 | 151 | Citations (PDF) |
| 231 | Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed | 4.2 | 507 | Citations (PDF) |
| 232 | Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patientsBlood, 2000, 95, 1950-1956 | 4.2 | 287 | Citations (PDF) |
